Deprescribing antipsychotics using multiple real patient cases
Deprescribing Antipsychotics: a Multiple Case Study
This project will see if reducing or stopping long-term antipsychotics works for adults with stable psychotic disorders by following real-world cases.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT07343193 on ClinicalTrials.gov |
What this trial studies
This is an observational multiple-case series at the psychiatry service of CHU de Strasbourg describing adults with psychotic or related disorders who accept or request deprescription of long-term antipsychotics. Eligible participants are clinically stable patients aged 18 or older who begin a planned reduction or discontinuation between January 1, 2021 and October 30, 2025; patients who refuse participation are excluded. The project records clinical decisions (who to deprescribe, timing, tapering rate, and relapse management) and outcomes from routine care to illustrate successes and challenges. The aim is to provide practical, real-life examples to inform clinicians and patients about deprescribing strategies and risks.
Who should consider this trial
Good fit: Adults (≥18) with a diagnosed psychotic or related disorder who are clinically stable on long-term antipsychotic treatment and who accept or request a planned deprescription are ideal candidates.
Not a fit: Patients who are clinically unstable, judged at high risk of relapse, or who decline to participate are unlikely to benefit from this project.
Why it matters
Potential benefit: If successful, the findings could give clinicians and patients practical examples to reduce unnecessary antipsychotic exposure and lessen treatment side effects for some people.
How similar studies have performed: Previous reports and trials have shown mixed results—some patients can taper successfully with careful plans, but relapse risk remains significant and consensus is lacking.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults (≥18 years) * Patients with a psychotic or related disorder * Patients on long-term antipsychotic treatment, clinically stable, who accept or request a deprescription between January 1, 2021, and October 30, 2025 Exclusion Criteria: \- Patients who have expressed their opposition to participating in the study
Where this trial is running
Strasbourg
- Service de Psychiatrie 1 - CHU de Strasbourg - France — Strasbourg, France (Recruiting)
Study contacts
- Study coordinator: Fabrice BERNA, MD, PhD
- Email: fabrice.berna@chru-strasbourg.fr
- Phone: 33 3 88 11 64 62
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.